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OCCURRENCE OF CO-COLONIZATION OR
CO-INFECTION WITH VANCOMYCIN-RESISTANT
ENTEROCOCCI AND METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS IN A MEDICAL INTENSIVE
CARE UNIT
David K. Warren, MD; Anand Nitin, MD; Cheri Hill, BS; Victoria J. Fraser, MD; Marin H. Kollef, MD
Until the development of the oxazolidinones and
quinupristin/dalfopristin, vancomycin had been the only
uniformly ef fective antibiotic for the treatment of
Staphylococcus aureus infections in the United States. In
1997, the first incidence of S. aureus with reduced sus-
ceptibility to vancomycin was described.1 This was fol-
lowed by at least eight reports of similar S. aureus strains
in the United States.2-6 Recently, two infections due to van-
comycin-resistant S. aureus have been described.7,8 Both
of these isolates contained the vanA gene, and in one of
the isolates, it was identical to the vanA gene present in
Enterococcus faecalis cultured from the same patient.7
These two reports suggest that the vanA gene was
acquired by S. aureus from vancomycin-resistant entero-
cocci (VRE) in these two patients having prior co-colo-
nization with methicillin-resistant S. aureus (MRSA) and
VRE.
The occurrence of colonization with VRE and
MRSA appears to be common among patients requiring
intensive care.9,10 MRSA has become the predominant
form of clinically significant S. aureus within intensive
care units (ICUs) and increasingly within some communi-
ty settings as well.9,11-15 However, there are few data indi-
cating the frequency with which concomitant colonization
or co-infection with MRSA and VRE occurs within the
same patient. Given the important clinical implications of
S. aureus developing vancomycin resistance, we per-
formed a clinical study in which the main goal was to
determine the occurrence of concomitant colonization or
co-infection with VRE and MRSA among patients admitted
to an ICU. 
METHODS
Study Location and Patients
This study was conducted at Barnes–Jewish
Hospital, a university-affiliated, urban teaching hospital
with 1,400 beds. During the 28-month period from
February 2000 to October 2001, all patients requiring
admission to the 19-bed medical ICU for more than 48
hours were eligible for this investigation. These inclusion
criteria were prospectively selected to minimize the
enrollment of patients with rapidly fatal illnesses and self-
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OBJECTIVE: To determine the occurrence of co-colo-
nization or co-infection with VRE and MRSA among medical
patients requiring intensive care. 
DESIGN: Prospective, single-center, observational study.
SETTING: A 19-bed medical ICU in an urban teaching
hospital.
PATIENTS: Adult patients requiring at least 48 hours of
intensive care and having at least one culture performed for
microbiologic evaluation. 
RESULTS: Eight hundred seventy-eight consecutive
patients were evaluated. Of these patients, 402 (45.8%) did not
have microbiologic evidence of colonization or infection with
either VRE or MRSA, 355 (40.4%) were colonized or infected with
VRE, 38 (4.3%) were colonized or infected with MRSA, and 83
(9.5%) had co-colonization or co-infection with VRE and MRSA.
Multiple logistic regression analysis demonstrated that increas-
ing age, hospitalization during the preceding 6 months, and
admission to a long-term–care facility were independently asso-
ciated with colonization or infection due to VRE and co-coloniza-
tion or co-infection with VRE and MRSA. The distributions of pos-
itive culture sites for VRE (stool, 86.7%; blood, 6.5%; urine, 4.8%;
soft tissue or wound, 2.0%) and for MRSA (respiratory secretions,
34.1%; blood, 32.6%; urine, 17.1%; soft tissue or wound, 16.2%)
were statistically different (P < .001). 
CONCLUSIONS: Co-colonization or co-infection with
VRE and MRSA is common among medical patients requiring
intensive care. The recent emergence of vancomycin-resistant
Staphylococcus aureus and the presence of a patient population co-
colonized or co-infected with VRE and MRSA support the need
for aggressive infection control measures in the ICU (Infect
Control Hosp Epidemiol 2004;25:99-104).
ABSTRACT
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limited conditions not requiring more prolonged intensive
care. The medical ICU is a closed unit with a multidisci-
plinary team providing patient care under the direction of
attending physicians who are board certified in critical
care medicine. This study was approved by the
Washington University School of Medicine Human
Studies Committee. 
Study Design and Data Collection
A prospective cohort study design was employed,
with the main outcome measure being concomitant colo-
nization or co-infection with VRE and MRSA. We also
assessed secondary outcomes including the lengths of
hospitalization and intensive care, the number of acquired
organ system derangements, and hospital mortality. 
For all patients included in the study, the following
characteristics were prospectively recorded by one of the
investigators: age; gender; ethnicity; severity of illness
based on Acute Physiology and Chronic Health Evaluation
II (APACHE II) scores16; the presence of congestive heart
failure, chronic obstructive pulmonary disease, underlying
malignancy, recent chemotherapy, seropositivity for human
immunodeficiency virus, diabetes mellitus, chronic renal
insufficiency, cirrhosis, and solid organ transplantation;
and the administration of corticosteroids.
One of the investigators made daily rounds in the
medical ICU to identify eligible patients. Patients included
in the study were prospectively observed until they were
discharged from the hospital or died. Discharge from the
hospital was defined as transfer of a patient from the hos-
pital to his or her home, a skilled nursing facility, or a pri-
vate rehabilitative hospital. All culture results and clinical
data were prospectively and independently reviewed by a
board-certified infectious disease physician (VJF).
Patients could not be entered into the study more than
once during the same hospitalization. 
Definitions
All definitions were selected prospectively as part of
the original study design. We calculated APACHE II scores
on the basis of the clinical data available from the first 24-
hour period of intensive care.16 The criteria for acquired
organ system derangements were those used by Rubin et
al.17 One point was given for acquired dysfunction of each
organ system. Renal dysfunction was defined as a twofold
increase in baseline creatinine level or an absolute increase
in baseline creatinine level of 2.0 mg/dL. Hepatic dysfunc-
tion was defined as an increase in total bilirubin level to
more than 2.0 mg/dL. Pulmonary dysfunction was defined
as one of the following: (1) a requirement for mechanical
ventilation for a diagnosis of pneumonia, chronic obstruc-
tive pulmonary disease, asthma, or pulmonary edema (car-
diogenic or noncardiogenic); (2) a PaO2 level of less than
60 mm Hg while receiving a fraction of inspired oxygen of
0.50 or more; or (3) the use of at least 10 cm of H2O of pos-
itive end-expiratory pressure. Neurologic dysfunction was
defined as a new focal deficit (eg, hemiparesis after cere-
bral infarction) or a new generalized process (eg, seizures
or coma). Gastrointestinal dysfunction was defined as gas-
trointestinal hemorrhage requiring transfusion, new ileus,
or diarrhea lasting more than 24 hours and unrelated to
previous bowel surgery. Cardiac dysfunction was defined
as acute myocardial infarction, cardiac arrest, or the new
onset of congestive heart failure.
Infection Control and Surveillance Protocol 
Healthcare workers and visitors were required to
wear both gloves and gowns before entry into rooms of
patients on contact isolation or contact precautions.
Contact precautions were used for patients colonized or
infected with VRE, MRSA, multidrug-resistant gram-nega-
tive bacilli, or Clostridium dif ficile. Additionally, a com-
mercially available alcohol-based disinfectant foam
(Alcare Plus, Steris Corporation, St. Louis, MO) or good
handwashing were required for hand disinfection prior to
all patient contacts. The alcohol-based foam was dis-
pensed from canisters placed at the entrance of every
patient room. These specific infection control practices
had previously been shown to reduce the acquisition of
VRE in this medical ICU.18
In conjunction with the contact precautions described,
the medical ICU employs specific protocols to reduce the
occurrence of hospital-acquired infections. Protocols direct-
ed at weaning patients from mechanical ventilation,19 reduc-
ing unnecessary sedation,20 and providing appropriate enter-
al nutritional support21 are in place and have been associated
with reductions in hospital-acquired infections. Additionally,
two education-based programs to reduce the occurrence of
ventilator-associated pneumonia and catheter-related blood-
stream infection, respectively, were employed in this ICU.22,23
As part of the ICU surveillance program, nurses
obtained samples for stool cultures or rectal swab cultures
for VRE from the patients on admission, weekly, and at the
time of discharge from the ICU.24 Bile esculin azide agar
with vancomycin (6 µg/mL; Remel, Lenexa, KS), followed
by a subculture on a 30-µg vancomycin disk, was used for
isolation, identification, and characterization of enteric
VRE, as described elsewhere.25 Because vanA and vanB
fail to produce inhibition zones of greater than 6 mm,
whereas vanC isolates primarily produce inhibition zones
of greater than 15 mm during subculturing on a 30-µg van-
comycin disk, this method reliably differentiates clinically
and epidemiologically relevant species.25 In addition, all
stool samples submitted for C. difficile testing were rou-
tinely tested for enteric VRE.25,26
A patient was considered to have enteric coloniza-
tion with VRE if a clinical culture or surveillance culture
of a rectal swab or stool sample was positive for VRE.
Colonization or infection with MRSA was defined as a pos-
itive clinical culture. Surveillance cultures from the nares
or other locations for MRSA were not routinely performed
during this investigation. 
Statistical Analysis
All comparisons were unpaired and all tests of sig-
nificance were two-tailed. Continuous variables were com-
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pared using the Student’s t test for normally distributed
variables and the Wilcoxon rank sum test for non-normal-
ly distributed variables. The chi-square or Fisher’s exact
test was used to compare categorical variables. The pri-
mary data analysis compared patients according to the
presence or absence of colonization or infection with VRE
and MRSA (alone or in combination). We performed mul-
tiple logistic regression analysis using a commercial sta-
tistical package (SPSS software, version 10.0 for
Windows; SPSS, Inc., Chicago, IL).
A stepwise approach was used to enter new terms
into the logistic regression model. Colonization or infec-
tion with VRE, colonization or infection with MRSA, and
co-colonization or co-infection with VRE and MRSA were
the three dependent outcome variables examined, and .05
was set as the limit for the acceptance or removal of new
terms. Variables with a P value of less than .15 were
entered into the multivariate analysis based on models
that were judged a priori to be clinically sound.27 This was
prospectively determined to be necessary to avoid pro-
ducing spuriously significant results with multiple com-
parisons. Results of the logistic regression analyses are
reported as adjusted odds ratios (ORs) with 95% confi-
dence intervals (CI95). Values are expressed as the mean
± standard deviation (continuous variables) or as a per-
centage of the group from which they were derived (cate-
gorical variables). All P values were two-tailed, and P val-
ues of .05 or less were considered to indicate statistical
significance.
RESULTS
Patients 
A total of 878 consecutive patients requiring admis-
sion to the medical ICU for more than 48 hours were eval-
uated. The mean age of the patients was 59.0 ± 17.0 years
(range, 15 to 102 years) and the mean APACHE II score
was 23.2 ± 7.4 (range, 5 to 47). There were 431 (49.1%)
male and 447 (50.9%) female patients.
Co-Colonization or Co-Infection With VRE and
MRSA
Four hundred two (45.8%) of the patients had no
microbiologic evidence of colonization or infection with
VRE or MRSA during their stay in the ICU. Three hun-
dred fifty-five (40.4%) of the patients had colonization or
infection with VRE, 38 (4.3%) of the patients had colo-
nization or infection with MRSA, and 83 (9.5%) of the
patients had co-colonization or co-infection with VRE and
MRSA. The distribution of the sites of infection is given
in Table 1. VRE was cultured statistically more often
from stool samples or rectal swabs compared with MRSA
(86.7% vs 0.0%; P < .001). MRSA was isolated more often
from respiratory secretions (34.1% vs 0.0%; P < .001) and
from blood (32.6% vs 6.5%; P < .001). Among all of the cul-
tures evaluated, 7 blood cultures were positive for VRE
and MRSA in the same patient. Two wound cultures
from the same patients were also positive for VRE and
MRSA.
Risk Factors for Colonization or Infection With
VRE and MRSA
Compared with patients who did not have coloniza-
tion or infection, patients with colonization or infection
due to VRE were statistically older and more likely to have
chronic obstructive pulmonary disease, chronic renal fail-
ure, outpatient hemodialysis, hospitalization during the 6
months preceding the current hospitalization, and admis-
sion to the ICU from a long-term–care facility (Table 2).
Similarly, patients with colonization or infection due to
MRSA were statistically older and more likely to have
chronic obstructive pulmonary disease, prior hospitaliza-
tion, and admission to the ICU from another hospital com-
pared with patients who did not have colonization or infec-
tion. Patients with colonization or infection due to MRSA
were statistically more likely to have underlying malig-
nancy and admission to the ICU from another hospital and
statistically less likely to have chronic renal failure com-
pared with patients colonized or infected with VRE.
Patients co-colonized or co-infected with VRE and MRSA
were statistically older and more likely to have chronic
obstructive pulmonary disease, prior hospitalization, and
admission to the ICU from a long-term–care facility com-
pared with patients who did not have colonization or infec-
tion with these microorganisms. Patients with 
co-colonization or co-infection with VRE and MRSA were
statistically less likely to have chronic renal failure and
outpatient dialysis compared with patients with coloniza-
tion or infection due to VRE.
Multiple logistic regression analysis showed that
increasing age (adjusted OR, 1.02; CI95, 1.01 to 1.03), hos-
pitalization during the 6 months preceding the current
hospitalization (adjusted OR, 2.74; CI95, 2.21 to 3.40), and
admission from a long-term–care facility (adjusted OR,
1.30; CI95, 1.14 to 1.47) were independently associated
with colonization or infection due to VRE. The same
three variables with similar adjusted ORs were indepen-
dently associated with co-colonization or co-infection with
VRE and MRSA. Prior hospitalization was the only vari-
able independently associated with colonization or infec-
tion due to MRSA (adjusted OR, 7.35; CI95, 3.96 to 
13.67). 
TABLE 1
SITES OF INFECTION
VRE MRSA
Site (n = 504) (n = 139)
Blood 33 (6.5%) 42 (32.6%)
Respiratory secretions 0 (0.0%) 44 (34.1%)
Urine 24 (4.8%) 22 (17.1%)
Soft tissue or wound 10 (2.0%) 21 (16.2%)
Rectum or stool 437 (86.7%) 0 (0.0%)*
VRE = vancomycin-resistant enterococci; MRSA = methicillin-resistant Staphylococcus aureus.
*MRSA was not actively screened for in the rectal or stool cultures due to the presence of van-
comycin-impregnated culture media.
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Secondary Outcomes
Patients with colonization or infection due to VRE
had statistically longer hospital stays compared with unin-
fected patients (Table 3). Patients with co-colonization or
co-infection with VRE and MRSA had statistically longer
stays in the hospital and in the ICU, longer duration of
mechanical ventilation, and a greater likelihood of hospi-
tal discharge to a long-term–care facility compared with
patients who did not have colonization or infection with
VRE and MRSA. 
DISCUSSION
We demonstrated that co-colonization or co-infec-
tion with VRE and MRSA was common among patients
admitted to a medical ICU, occurring in 9.5%. Increasing
patient age, hospitalization during the preceding 6
months, and admission to the ICU from a long-term–care
facility were identified as independent risk factors for co-
colonization or co-infection with VRE and MRSA. Co-colo-
nized or co-infected patients also had statistically longer
stays in the hospital and ICU and were statistically more
likely to require admission to a long-term–care facility fol-
lowing hospital discharge compared with patients who did
not have VRE and MRSA colonization or infection. 
Despite the widespread presence of patients colo-
nized or infected with VRE and MRSA in ICUs, no previ-
ous study has examined the occurrence of co-colonization
or co-infection with these gram-positive bacteria within
the same patient in this clinical setting. Previous investi-
gations among hospitalized patients and patients in
skilled-care facilities suggest that those colonized with
VRE are at increased risk for colonization or infection
TABLE 2
PATIENT CHARACTERISTICS ACCORDING TO MICROORGANISM
Patients With Patients With Patients With Patients With
Neither VRE MRSA Both VRE
VRE or MRSA Only Only and MRSA
Characteristic (n = 402) (n = 355) (n = 38) (n = 83)
Mean age, y (± SD) 56.3 (± 17.3) 60.4 (± 16.7)* 62.6 (± 17.4)* 63.9 (± 13.4)*
Gender
Male 191 (47.5%) 174 (49.0%) 19 (50.0%) 47 (56.6%)
Female 211 (52.5%) 181 (51.0%) 19 (50.0%) 36 (43.4%)
Ethnicity
White 248 (61.7%) 197 (55.5%) 27 (71.1%) 54 (65.1%)
Black 151 (37.6%) 153 (43.1%) 11 (28.9%) 26 (31.3%)
Other 3 (0.7%) 5 (1.4%) 0 (0.0%) 3 (3.6%)
Mean APACHE II score (± SD) 23.8 (± 7.4) 24.7 (± 6.7) 24.2 (± 6.2) 25.4 (± 7.7)
Surgery 30 (7.5%) 20 (5.6%) 1 (2.6%) 9 (10.8%)
Congestive heart failure 70 (17.4%) 69 (19.4%) 7 (18.4%) 16 (19.3%)
COPD 93 (23.1%) 111 (31.3%)* 15 (39.5%)* 31 (37.3%)*
Underlying malignancy 48 (11.9%) 29 (8.2%) 8 (21.1%)† 8 (9.6%)
Chemotherapy 10 (2.5%) 5 (1.4%) 2 (5.3%) 0 (0.0%)
HIV positive 14 (3.5%) 16 (4.5%) 0 (0.0%) 0 (0.0%)
Diabetes mellitus 120 (29.9%) 126 (35.5%) 14 (36.8%) 39 (47.0%)
Received corticosteroids 146 (36.3%) 142 (40.0%) 10 (26.3%) 32 (38.6%)
Chronic renal failure 99 (24.6%) 117 (33.0%)* 6 (15.8%)† 17 (20.5%)†
Outpatient hemodialysis 33 (8.2%) 56 (15.8%)* 3 (7.9%) 5 (6.0%)†
Cirrhosis 38 (9.5%) 22 (6.2%) 2 (5.3%) 6 (7.2%)
Organ transplant 21 (5.2%) 29 (8.2%) 2 (5.3%) 5 (6.0%)
Prior hospitalization 138 (34.3%) 205 (57.7%)* 22 (57.9%)* 41 (49.4%)*
Admission location
Other hospital 105 (26.1%) 63 (17.7%)* 16 (42.1%)*,† 19 (22.9%)*,‡
Hospital ward 161 (40.0%) 184 (51.8%) 7 (18.4%) 33 (39.8%)
Home 126 (31.3%) 73 (20.6%) 13 (34.2%) 19 (22.9%)
Long-term–care facility 10 (2.5%) 35 (9.9%) 2 (5.3%) 12 (14.5%)
VRE = vancomycin-resistant enterococci; MRSA = methicillin-resistant Staphylococcus aureus; SD = standard deviation; APACHE = Acute Physiology and Chronic Health Evaluation; COPD = chronic
obstructive pulmonary disease; HIV = human immunodeficiency virus.
*P < .05 for comparison with the group who had neither organism cultured.
†P < .05 for comparison with the group who had VRE identified in culture.
‡P < .05 for comparison with the group who had MRSA identified in culture.
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with MRSA and S. aureus displaying intermediate resis-
tance to vancomycin.28-30 The clinical importance of co-col-
onization or co-infection with these pathogens is high-
lighted by the recent description of vancomycin-resistant
S. aureus occurring as a result of the transfer of the vanA
gene from VRE.7,8 Although the acquired vancomycin-
resistant genes vanA, vanB, vanD, vanE, vanF, and vanG
have been reported in VRE, transfer of the vanA gene to
S. aureus appears to be a rare event.7 This suggests that
the transfer requires specific conditions as suggested by
the difficulty encountered attempting in vitro conjugate
transfer of the vanA gene from enterococci to S. aureus.31
Although recommended measures to control the
spread of VRE and MRSA in hospitals have been promot-
ed for several years, surveillance data suggest that the
existence of these recommendations has not appreciably
slowed the increasing rate of infection or colonization
with either of these organisms in the United States.32,33
The reasons for this lack of effect are unclear and under
debate. In some institutions, the recommended measures
may be ineffective or poorly followed or implemented.
However, increasing evidence suggests that well-targeted
intervention programs implemented within motivated
healthcare environments can reduce the occurrence of
colonization as well as infection with these antibiotic-resis-
tant, gram-positive bacteria. 
Our study has several limitations. First, it was per-
formed within a single ICU with relatively high rates of
colonization or infection with VRE, especially among
patients admitted from other healthcare settings.
Therefore, the results may not be generalizable to ICUs
and hospitals with different sources of patient referral.
However, the escalating rates of VRE and MRSA in the
United States suggest that co-colonization or co-infection
with these bacteria is likely to be a more widespread
occurrence. Second, we did not differentiate colonization
from infection in this study. This was purposefully done
because our intent was to identify the coexistence of VRE
and MRSA among the same patients. Third, we did not
specifically examine the use of antibiotics as a risk factor
for the acquisition of VRE and MRSA as has been previ-
ously reported.32 However, recent investigations have
found that patients with healthcare-acquired sources of
infection have bacterial pathogens associated with infec-
tion that are similar to those seen in hospital-acquired
infection, and that antibiotic exposure is common among
these patients.34
Another important potential limitation of our study
is that we examined only clinical cultures for MRSA, and
although we performed active surveillance of VRE, we
used a selective medium for stool cultures containing van-
comycin to select out for VRE. Therefore, we likely
underestimated the occurrence of colonization and infec-
tion with MRSA in this population. This underreporting
bias also limits the accuracy of the risk factors for infec-
tion and colonization with MRSA identified in this analy-
sis. Other investigators have estimated that approximate-
ly 55% of patients colonized with MRSA are detected by
clinical cultures alone compared with clinical cultures
combined with active surveillance.35,36 With the use of this
approximation, it is likely that the true incidence of co-col-
onization or co-infection with VRE and MRSA is closer to
15% or 20%. Finally, we did not differentiate between
patients colonized or infected with MRSA and VRE on
admission to the ICU and patients who acquired these
pathogens during their stay in the ICU. As a result, the
risk factors identified for colonization or infection with
these organisms may not be applicable to specific patient
subgroups (eg, patients acquiring VRE, MRSA, or both
while in the ICU).
TABLE 3
CLINICAL OUTCOMES
Patients With Patients With Patients With Patients With
Neither VRE MRSA Both VRE
Outcome VRE or MRSA Only Only and MRSA
Variable (n = 402) (n = 355) (n = 38) (n = 83)
Mean no. of acquired organ system 1.8 (± 1.1) 1.8 (± 1.0) 1.6 (± 1.0) 1.7 (± 1.0)
derangements (± SD)
Mean hospital stay, d (± SD) 22.1 (± 22.8) 28.3 (± 29.4)* 27.8 (± 27.2) 29.4 (± 24.2)*
Mean ICU stay, d (± SD) 9.1 (± 8.0) 9.8 (± 8.6) 10.1 (± 7.4) 13.3 (± 10.3)*,†
Mean duration of mechanical ventilation, d (± SD) 10.6 (± 12.0) 12.3 (± 14.3) 10.6 (± 8.1) 17.8 (± 20.8)*,†
Disposition of hospital survivors
Home 182 (60.7%) 119 (52.9%) 15 (55.6%) 22 (40.0%)*
Long-term–care facility 102 (34.0%) 96 (42.7%) 11 (40.7%) 31 (56.4%)*
Outside hospital 16 (5.3%) 10 (4.4%) 1 (3.7%) 2 (3.6%)
VRE = vancomycin-resistant enterococci; MRSA = methicillin-resistant Staphylococcus aureus; SD = standard deviation; ICU = intensive care unit.
*Comparison with the group who had neither organism cultured.
†Comparison with the group who had VRE identified in culture.
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Despite these limitations, we demonstrated that co-
infection with VRE and MRSA is common among critical-
ly ill patients. Clinicians should be aware of the potential
for co-infection with VRE and MRSA in the ICU setting.
Appropriate infection control practices should be in place
to limit the horizontal transmission of VRE and MRSA to
minimize the future potential for concomitant colonization
or co-infection and the transfer of resistance genes among
these pathogens.
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